ATE82274T1 - Morphologisch homogene formen von famotidin und verfahren zu deren herstellung. - Google Patents

Morphologisch homogene formen von famotidin und verfahren zu deren herstellung.

Info

Publication number
ATE82274T1
ATE82274T1 AT87306882T AT87306882T ATE82274T1 AT E82274 T1 ATE82274 T1 AT E82274T1 AT 87306882 T AT87306882 T AT 87306882T AT 87306882 T AT87306882 T AT 87306882T AT E82274 T1 ATE82274 T1 AT E82274T1
Authority
AT
Austria
Prior art keywords
famotidin
production
homogeneous forms
morphologically homogeneous
morphologically
Prior art date
Application number
AT87306882T
Other languages
English (en)
Inventor
Peter Bod
Kalman Harsanyi
Bela Hegedus
Erik Bogsch
Eva Fekecs
Imre Peter
Zsuzsanna Aracs
Sandor Miszori
Maria Stiller
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10963778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE82274(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Application granted granted Critical
Publication of ATE82274T1 publication Critical patent/ATE82274T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT87306882T 1986-08-05 1987-08-04 Morphologisch homogene formen von famotidin und verfahren zu deren herstellung. ATE82274T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU863370A HU196775B (en) 1986-08-05 1986-08-05 Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
EP87306882A EP0256747B2 (de) 1986-08-05 1987-08-04 Morphologisch homogene Formen von Famotidin und Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
ATE82274T1 true ATE82274T1 (de) 1992-11-15

Family

ID=10963778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87306882T ATE82274T1 (de) 1986-08-05 1987-08-04 Morphologisch homogene formen von famotidin und verfahren zu deren herstellung.

Country Status (18)

Country Link
US (3) US4894459A (de)
EP (1) EP0256747B2 (de)
JP (2) JP2644234B2 (de)
KR (1) KR940003954B1 (de)
CN (1) CN1024275C (de)
AR (1) AR243175A1 (de)
AT (1) ATE82274T1 (de)
AU (1) AU604040B2 (de)
BG (1) BG60496B2 (de)
CA (1) CA1265809A (de)
CS (1) CS268188B2 (de)
DE (2) DE256747T1 (de)
DK (1) DK175022B1 (de)
FI (1) FI89917C (de)
GR (1) GR871216B (de)
HU (1) HU196775B (de)
PH (1) PH24069A (de)
PT (1) PT85473B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO882037L (no) * 1987-06-22 1988-12-23 Marga Para La Investigacion Sa Famotidin, polymerte former og fremstilling derav.
WO1995001782A2 (en) * 1993-07-09 1995-01-19 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
CA2426122A1 (en) * 2002-05-02 2003-11-02 M/S Tonira Pharma Limited A process for the preparation of a combination of famotidine polymorphis a and b
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
CL2003002588A1 (es) * 2002-12-11 2005-01-07 Taro Pharmaceuticals Ireland L Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
EP1781624A4 (de) * 2004-07-02 2010-06-23 Taro Pharma Ind Verfahren zur herstellung von 1-methoxymethyl-5,5-diphenylbarbitursäure
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
CA2615496C (en) * 2005-07-18 2014-11-18 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
EP2438919A1 (de) 2006-07-18 2012-04-11 Horizon Pharma USA, Inc. Zusammensetzungen Famotidin und Ibuprofen enthaltend sowie Zusammensetzungen 25 mg bis 28 mg Famotidin enthaltend.
WO2008027963A2 (en) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
WO2008066704A2 (en) * 2006-11-14 2008-06-05 Taro Pharmaceuticals North America, Inc. Method of improving bioavailability for non-sedating barbiturates
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
TR201618765A2 (tr) 2016-12-16 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları.
JP2023534810A (ja) 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1543238A (en) * 1976-09-21 1979-03-28 Smith Kline French Lab Polymorph of cimetidine
JPS6056143B2 (ja) * 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
JPS5655383A (en) * 1979-10-12 1981-05-15 Yamanouchi Pharmaceut Co Ltd Amizine derivative and its preparation
HU185457B (en) * 1981-09-25 1985-02-28 Richter Gedeon Vegyeszet Process for preparating cimetidine-z
US4496737A (en) * 1982-09-27 1985-01-29 Merck & Co., Inc. Process for preparing sulfamylamidine antisecretory agents
JPS59227870A (ja) * 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
HU194845B (en) * 1985-09-11 1988-03-28 Richter Gedeon Vegyeszet Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin
DE3644246A1 (de) * 1986-06-20 1987-12-23 Uriach & Cia Sa J Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
NO882037L (no) * 1987-06-22 1988-12-23 Marga Para La Investigacion Sa Famotidin, polymerte former og fremstilling derav.

Also Published As

Publication number Publication date
JP2644234B2 (ja) 1997-08-25
HU196775B (en) 1989-01-30
FI873346A0 (fi) 1987-08-03
DK404187D0 (da) 1987-08-03
JPS6399065A (ja) 1988-04-30
US5128477A (en) 1992-07-07
CA1265809A (en) 1990-02-13
EP0256747B1 (de) 1992-11-11
DK404187A (da) 1988-02-06
GR871216B (en) 1987-11-19
CN1024275C (zh) 1994-04-20
DK175022B1 (da) 2004-04-26
EP0256747B2 (de) 2001-11-28
DE256747T1 (de) 1988-11-24
FI89917C (fi) 1993-12-10
KR940003954B1 (ko) 1994-05-09
HUT45240A (en) 1988-06-28
PH24069A (en) 1990-03-05
KR880002847A (ko) 1988-05-11
CS579987A2 (en) 1989-04-14
PT85473A (en) 1987-09-01
BG60496B2 (bg) 1995-05-31
AU604040B2 (en) 1990-12-06
US4894459A (en) 1990-01-16
JPH07316141A (ja) 1995-12-05
AR243175A1 (es) 1993-07-30
PT85473B (pt) 1990-06-29
DE3782576T3 (de) 2002-08-08
DE3782576T2 (de) 1993-03-25
EP0256747A1 (de) 1988-02-24
CS268188B2 (en) 1990-03-14
FI873346L (fi) 1988-02-06
DE3782576D1 (de) 1992-12-17
JP2708715B2 (ja) 1998-02-04
AU7654287A (en) 1988-02-11
FI89917B (fi) 1993-08-31
CN87105373A (zh) 1988-06-08
US5120850A (en) 1992-06-09

Similar Documents

Publication Publication Date Title
DE3782576D1 (de) Morphologisch homogene formen von famotidin und verfahren zu deren herstellung.
DE3789881D1 (de) Verfahren zur Herstellung von Photomasken und Photomaske.
DE3887625D1 (de) Verfahren zur Herstellung von 1,1,1-Trifluorodichlorethan und von 1,1,1,2-Tetrafluorchlorethan.
ATE98964T1 (de) Zusammensetzungen welche komplexe von hyaluronsaeure enthalten und verfahren zu deren herstellung.
DE3770675D1 (de) Trockenuebertragungsmaterial von musterungen und verfahren zu seiner herstellung.
DE3885794D1 (de) Zusammensetzung von aromatischem Polyester und Verfahren zu deren Herstellung.
ATE96174T1 (de) Verfahren zur herstellung von avermectine-b und die verwendeten kulturen.
DE3785163D1 (de) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-en-2-carbonsaeurederivate und verfahren zu deren herstellung.
DE68927703D1 (de) Verfahren zur Herstellung von 2,3-Dimethylbutenen
DE3888217D1 (de) Supraleitende Zusammensetzungen und Verfahren zu deren Herstellung.
DE69024909D1 (de) Verfahren zur Herstellung von Polyimid-Verbundstoffen
DE3777668D1 (de) Schmelzgesponnene kohlenstoffasern von hoher festigkeit und verfahren zu deren herstellung.
DE3780532D1 (de) Amphoterische staerke und verfahren zu deren herstellung.
DE3852426D1 (de) Gemischter Supraleiter und Verfahren zu seiner Herstellung.
DE68927949D1 (de) 3,9-Diphosphaspiroundecane und Verfahren zur Herstellung von 3,9-Diphosphaspiroundecanen
ATE103959T1 (de) Polymer-metallverbundstoff und verfahren zu seiner herstellung.
DE3855073D1 (de) Verfahren zur Herstellung von feinsten Metallfilmen und feinsten Metallbildern
ATE112568T1 (de) Verfahren zur herstellung von 9-substituierten guaninderivaten und zwischenprodukte zur verwendung im verfahren.
DE59001670D1 (de) Verfahren und anlage zur herstellung von dicalciumphosphat.
DE3887445D1 (de) Verfahren zur herstellung von glukagonhomologen und deren verwendung.
DE69029066D1 (de) Abkömmlinge von fluorierten Carbonsäuren und Verfahren zu deren Herstellung
DE3788205D1 (de) Etikett und Verfahren zu seiner Herstellung.
DE69023681D1 (de) Verfahren zur Herstellung von Restriktionsendonuklease und -Methylase-MwoI.
DE59004582D1 (de) 1,3-Di-arylmethoxy-4,6-dinitrobenzole, Verfahren zu ihrer Herstellung und Verfahren zur Herstellung von 4,6-Diaminoresorcin.
DE3485058D1 (de) Wasserloesliche formen von polyenantibiotika und verfahren zu ihrer herstellung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time